POMONA, Calif.--(BUSINESS WIRE)-- Eurofins Environment Testing Eaton Analytical, part of the Eurofins Environment Testing network of laboratories in the US and a leader in water quality analysis, has introduced a cutting-edge method to detect chloronitramide anion, a newly identified disinfection byproduct (DBP), in drinking water. This innovation follows a pivotal study published in that identified chloronitramide anion as a previously unidentified decomposition product of chloramine disinfection. Chloramine disinfection, also known as chloramination, is used by approximately one-third of ...
NORTHAMPTON, England--(BUSINESS WIRE)-- , a full-service provider for retailers, brands, and manufacturers of consumer products, has grown its extensive service offering to include a that tests for Volatile Organic Compounds (VOCs). Given that VOCs pose significant concerns for human health and the environment, increasingly stringent regulations and heightened pressure on businesses to effectively manage VOCs have emerged. In light of this, in August 2024, Zero Discharge of Hazardous Chemicals (ZDHC) issued the ZDHC Air Emissions Guidelines V1.0, which focuses on VOC emissions from input form...
>Update on the key messages by division - Biopharma: the group has lost two major contracts (due to the success of clinical testing which has enabled clients to move the later stages more rapidly than expected, not due to any calling into question of Eurofins), and a third contract that has been significantly reduced for similar reasons. The group stressed that new major contracts should take over in H2 2025. In agriscience, management acknowledged the weak visibility...
>Point sur les principaux messages par division. - Biopharma : le groupe a perdu deux contrats importants (à cause du succès des tests cliniques qui ont permis aux clients de passer à des étapes ultérieures plus rapidement que prévu, pas à cause de remise en cause d’Eurofins), et un troisième a fortement baissé pour des raisons similaires. Le groupe a insisté sur le fait que de nouveaux contrats d’ampleur viendraient prendre le relai à partir du S2 2025. Sur l’agrosci...
>Principal point de la confcall : décryptage de la baisse de la division Biopharma - Le groupe a tenu sa conf call hier à 15h, et le titre a clôturé en baisse de 11.2%. Bien que la sanction boursière nous semble un peu sévère, elle peut être expliquée par l’accumulation de plusieurs points négatif, malgré une performance globalement satisfaisante. Voici les principaux points que nous retenons :Précisions sur la division Biopharma : la croissance en Amériques du...
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
>Main takeaway from the conference call: explanation for the decline in the Biopharma division - The group held a conference call yesterday at 3.00pm and the share closed down -11.2%. Although the market sanction looks a bit harsh, it can be explained by the accumulation of several negative points, despite a broadly satisfactory performance. Our main takeaways are as follow: Further details on the biopharma division: growth in North America was more moderate, d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.